A5004540819- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- Kruppel-like factors research
- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- Retinoids in leukemia and cellular processes
- Hedgehog Signaling Pathway Studies
- Frailty in Older Adults
- Extracellular vesicles in disease
- Cancer therapeutics and mechanisms
- Chromatin Remodeling and Cancer
- Cutaneous lymphoproliferative disorders research
- Histone Deacetylase Inhibitors Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Renal Diseases and Glomerulopathies
Ospedale Annunziata di Cosenza
2023-2025
Azienda Ospedaliera di Cosenza
2024-2025
Magna Graecia University
2022-2024
Introduction Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).
Introduction Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib fedratinib, which target Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with persistence, even worsening anemia remains significant challenge, leading usually to treatment discontinuation.
Introduction Acute myeloid leukemia (AML) encompasses a heterogeneous group of aggressive malignancies, where FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent, accounting for approximately 25-30% adult patients. The presence this mutation is related to dismal prognosis and high relapse rates. In the lasts years many FLT3 inhibitors have been developed.
ABSTRACT Therapy‐related acute promyelocytic leukemia (t‐APL) is rare and often linked to previous treatment with alkylating agents or topoisomerase II inhibitors. This report describes three cases of t‐APL treated at the Haematology Department Cosenza Hospital between 2022 2024, which occurred after exemestane, radiation therapy, agents, taxane, checkpoint inhibitor, respectively. Each case was managed a different therapeutic approach. The first involved 71‐year‐old man colorectal breast...
Long-term survival induced by anticancer treatments discloses emerging frailty among breast cancer (BC) survivors. Trastuzumab-induced cardiotoxicity (TIC) is reported in at least 5% of HER2+BC patients. However, TIC mechanism remains unclear and predictive genetic biomarkers are still lacking. Interaction between systemic inflammation, cytokine release ADME genes patients might contribute to explain mechanisms underlying individual susceptibility drug response variability. We present a...
Over the last few years, substantial progress has been made in management of acute myeloid leukemia (AML). The first changes AML date back to 2000s with advent hypometilant agents, later Bcl2 inhibitor venetoclax, and Fms-like tyrosine kinase 3 (FLT3) inhibitors (midostaurin gilteritinib), more recently IDH1/2 (ivosidenib enasidenib) hedgehog (HH) pathway glasdegib.Glasdegid, formerly PF-04449913 or PF-913, acts as a smoothened (SMO) approved combination low-dose cytarabine (LDAC) by FDA EMA...
Carboplatin is the cornerstone of ovarian cancer (OC) treatment, while platinum-response, dependent on interindividual variability, major prognostic factor for long-term outcomes. This retrospective study was focused explorative search genetic polymorphisms in Absorption, Distribution, Metabolism, Excretion (ADME) genes identification biomarkers prognostic/predictive platinum-response OC patients. Ninety-two advanced patients treated with carboplatin-based therapy were enrolled at our...
Thrombotic thrombocytopenic purpura (TTP) is a potentially life-threatening, rare acute thrombotic microangiopathy (TMA), caused by severe ADAMTS13 deficiency. As the COVID-19 pandemic rapidly spread around globe, much data about pathogenicity of this virus were published. Soon after detection first cases COVID-19, it was clear that there wide range COVID coagulopathy manifestations, such as deep venous thrombosis, pulmonary thromboembolism, and microangiopathies. In literature, little have...